Pre‐diagnostic derivatives of reactive oxygen metabolites and the occurrence of lung, colorectal, breast and prostate cancer: An individual participant data meta‐analysis of two large population‐based studies

Oxidative stress may be involved in carcinogenesis and biomarkers of oxidative stress like derivatives of reactive oxygen metabolites (d‐ROM) may be useful for cancer prediction. However, no previous study assessed the association of pre‐diagnostic d‐ROM measurements with cancer incidence. We measured d‐ROM in a cohort sample of n = 4,345 participants of the German ESTHER study and in a case‐cohort sample of the Norwegian Tromsø study (cancer cases: n = 941; sub‐cohort: n = 1,000). Moreover, d‐ROM was repeatedly measured at follow‐ups of both studies. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were derived by (weighted) multivariable‐adjusted Cox regression with time‐dependent modelling of d‐ROM levels for incident lung, colorectal, breast and prostate cancer. Individual study results were pooled by random effects meta‐analysis. The HRs (95% CI) between top and bottom d‐ROM tertile were statistically significantly different for lung (1.90 [1.25‐2.89]), colorectal (1.70 [1.15‐2.51]) and breast cancer incidence (1.45 [1.01‐2.09]) but not for prostate cancer incidence (1.20 [0.84‐1.72]). In conclusion, this individual participant data meta‐analysis of two large population‐based cohort studies with repeated d‐ROM measurements yielded evidence for an involvement of high oxidative stress in carcinogenesis. Given the observed associations of pre‐diagnostic d‐ROM measurements with lung, colorectal and breast cancer incidence, subjects with increased serum d‐ROM levels should be recommended to reduce these levels by lifestyle changes including smoking cessation, a healthy diet and an increase in physical activity.

This article is protected by copyright. All rights reserved.

https://ift.tt/2SajnX2